Takeda Pharmaceutical has a robust drug discovery pipeline to meet future clinical demand. Check out the upside and downside ...
Takeda is sharpening its oncology focus amid an R&D revamp. Sun Pharma will acquire Checkpoint Therapeutics and an ...
Takeda’s revamped R&D strategy means the drugmaker’s oncology leaders are prioritizing work in tumors across thoracic, gastrointestinal (GI) and hematology, while pushing the Japanese company’s cell ...
M&T Bank Corp lowered its position in Takeda Pharmaceutical Company Limited (NYSE:TAK – Free Report) by 10.0% in the 4th ...
Yardbarker on MSN16h
Collin Morikawa and Rio Takeda Rewrite the Script of DominanceGolf, often a game of patience and calculated risks, has a way of humbling even the greatest players. Just when it seems like ...
The pharma giant announced a new partnership with BridGene Biosciences that will use its IMTAC platform for drug discovery.
Takeda’s $300 million bet on Protagonist Therapeutics’ hematology asset a year ago appears to have paid off as the drug ...
Takeda Pharmaceutical teamed up with the Boston Celtics to raise awareness of rare diseases at the C’s-Cavaliers game on ...
Rio Takeda shot a blistering 8-under 64 to win the LPGA’s Blue Bay tournament by six shots ahead of Minjee Lee of Australia.
The Associated Press – Sports on MSN6d
Rio Takeda takes a 2-shot lead into the final round of the LPGA tournament in ChinaRio Takeda of Japan shot a 3-under 69 to hold a two-shot lead after three rounds of the LPGA’s Blue Bay tournament on China’s ...
Rio Takeda shot a blistering 8-under 64 to win the LPGA's Blue Bay tournament by six shots ahead of Minjee Lee.
SANYA, China — Rio Takeda shot a blistering 8-under 64 on Sunday to win the LPGA’s Blue Bay tournament by six shots ahead of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback